Dr. Reddy's Laboratories reported a 69% decline in Q1 FY27 net profit to ₹443 crore, weighed down by the conclusion of its profitable Revlimid generic sales and a temporary halt in semaglutide shipments. The company is now re-focusing on biosimilars and innovation to navigate a challenging U.S. generics market.
Dr. Reddy's Laboratories has reported a difficult first quarter for fiscal year 2027, with net profit falling 69% year-on-year to ₹443 crore. Revenue for the period also declined 6% to ₹8,071 crore. This performance reflects a major transition for the company as it moves past a period of reliance on high-margin generic drug sales toward a new, more diversified business model.
The End of the Revlimid Windfall
The company’s recent earnings were significantly impacted by the conclusion of its arrangement to sell generic lenalidomide, marketed as Revlimid. This product had been a major contributor to the company’s bottom line for several years. With the volume limits of the settlement agreement expiring on January 31, 2026, the era of exclusive, high-margin revenue from this drug has ended. Management has characterized such past opportunities as temporary windfalls rather than sustainable, long-term revenue streams, emphasizing the need for the business to build different sources of profit.
Operational Hurdles with Semaglutide
Adding to the earnings pressure, the company faced a specific operational setback involving semaglutide, the active ingredient used in popular weight-loss and diabetes treatments. A quality issue, specifically an out-of-specification impurity, forced a voluntary halt in shipments. This incident resulted in a one-time provision of ₹240 crore. The company has revised its supply targets for the full year to 6–7 million pens. Investors are now looking toward the expected resumption of commercial shipments, which management anticipates will take place in late October or early November 2026.
Pivoting Toward Biosimilars and Innovation
In response to these challenges, Dr. Reddy's is shifting its strategic focus. The U.S. generics market, while still a part of the business, is currently experiencing intense pricing pressure as competition for generic products increases. To offset this, the company is intensifying its focus on biosimilars, consumer health, and in-licensed drug products. A notable recent milestone in this strategy was the U.S. FDA approval for its version of the rituximab biosimilar, which marks a step forward in its biologics pipeline.
Risks and Future Monitorables
Beyond the immediate operational issues, the company faces broader risks, including strict regulatory compliance requirements and the ongoing difficulty of maintaining profit margins in the highly competitive U.S. generic drug market. The success of the company’s pivot will depend on its ability to execute its expansion into biosimilars and other innovative therapies while managing the cost pressures currently affecting the global pharmaceutical supply chain.
The most important update for shareholders to track in the coming months will be the successful resumption of semaglutide shipments and any further progress the company makes in scaling its biosimilar product pipeline.